Edition:
India

Integra LifeSciences Holdings Corp (IART.OQ)

IART.OQ on NASDAQ Stock Exchange Global Select Market

47.58USD
22 Nov 2017
Change (% chg)

$-0.16 (-0.34%)
Prev Close
$47.74
Open
$47.55
Day's High
$47.79
Day's Low
$47.30
Volume
133,457
Avg. Vol
207,306
52-wk High
$56.39
52-wk Low
$37.71

Chart for

About

Integra LifeSciences Holdings Corporation is a medical technology company. The Company focuses on the development, manufacturing, and marketing of surgical implants and medical instruments. Its segments include Specialty Surgical Solutions, which offers specialty surgical instrumentation for a range of specialties, including... (more)

Overall

Beta: 0.66
Market Cap(Mil.): $4,021.81
Shares Outstanding(Mil.): 78.08
Dividend: --
Yield (%): --

Financials

BRIEF-Integra Lifesciences Q3 adjusted earnings per share $0.45

* Integra Lifesciences reports third quarter 2017 financial results

26 Oct 2017

BRIEF-JNJ announces completion of Codman Neurosurgery divestiture to Integra Lifesciences

* Johnson & Johnson announces completion of Codman Neurosurgery divestiture to Integra Lifesciences Holding Corporation Source text for Eikon: Further company coverage:

03 Oct 2017

U.S. FTC approves Integra purchase of J&J’s Codman business

WASHINGTON Medical device maker Integra LifeSciences Holdings Corp has received U.S. antitrust approval to buy Johnson & Johnson's Codman Neuro Division, the Federal Trade Commission said on Wednesday.

27 Sep 2017

UPDATE 1-U.S. FTC approves Integra purchase of J&J’s Codman business

WASHINGTON, Sept 27 Medical device maker Integra LifeSciences Holdings Corp has received U.S. antitrust approval to buy Johnson & Johnson's Codman Neuro Division, the Federal Trade Commission said on Wednesday.

27 Sep 2017

FTC allows Integra to buy J&J’s Codman neuro business, with conditions

WASHINGTON, Sept 27 Medical device maker Integra LifeSciences Holdings Corp has received U.S. antitrust approval to buy Johnson & Johnson's Codman Neuro Division, the Federal Trade Commission said on Wednesday.

27 Sep 2017

BRIEF-Integra lifesciences reports preliminary assessment of damage to Puerto Rico facility

* Integra Lifesciences provides preliminary assessment of minor damage to its manufacturing facility in Añasco, Puerto Rico

26 Sep 2017

BRIEF-Integra LifeSciences announces first patient enrolled in Cadence® total ankle system post-market study

* Integra LifeSciences announces first patient enrolled in Cadence® total ankle system post-market study Source text for Eikon: Further company coverage:

22 Sep 2017

BRIEF-Natus to acquire neurosurgery assets from Integra Lifesciences

* Natus to acquire neurosurgery assets from Integra Lifesciences, enters neurosurgery market

11 Sep 2017

BRIEF-Integra Lifesciences to sell neurosurgery assets to Natus Medical

* Integra Lifesciences announces definitive agreement to sell certain neurosurgery assets to Natus Medical Incorporated

11 Sep 2017

BRIEF-Integra Lifesciences reports Q2 adjusted earnings of $0.45/shr

* Integra lifesciences reports second quarter 2017 financial results

26 Jul 2017

Earnings vs. Estimates